Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2013

Mao Muling, Tian Feng, Mariadason John M, Tsao Chun C, Lemos Robert, Dayyani Farshid, Gopal Y N Vashisht, Jiang Zhi-Qin, Wistuba Ignacio I, Tang Xi M, Bornman William G, Bollag Gideon, Mills Gordon B, Powis Garth, Desai Jayesh, Gallick Gary E, Davies Michael A, Kopetz Scott

Abstract excerpt

PURPOSE: Vemurafenib, a selective inhibitor of BRAF(V600), has shown significant activity in BRAF(V600) melanoma but not in less than 10% of metastatic BRAF(V600) colorectal cancers (CRC), suggesting that studies of the unique hypermethylated phenotype and concurrent oncogenic activation of BRAF(...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methylation

Share to Mitogen-Activated Protein Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to PTEN Phosphohydrolase

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 23251002
DOI: 10.1158/1078-0432.CCR-11-1446
PMCID: PMC3563727

Genes

BRAF
PTEN
EGF
EGFR
KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23251002-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.PMID 23251002Read ↗

Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.Semantic proximity Read ↗

New therapeutic strategies for BRAF mutant colorectal cancers.Semantic proximity Read ↗

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in <i>BRAF</i> -Mutated MelanomaSemantic proximity Read ↗

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.Semantic proximity Read ↗

Emerging treatment options for BRAF-mutant colorectal cancerSemantic proximity Read ↗

PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaSemantic proximity Read ↗

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with VemurafenibSemantic proximity Read ↗

Targeted Therapy for Colorectal Cancers With Non-V600 BRAF Mutations: Perspectives for Precision OncologySemantic proximity Read ↗

ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.Semantic proximity Read ↗

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.Semantic proximity Read ↗

MAPK inhibition in BRAFV600E CRC.Semantic proximity Read ↗

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.